Skip to main content

Peer Review reports

From: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)

Original Submission
30 Oct 2019 Submitted Original manuscript
21 Jan 2020 Reviewed Reviewer Report - Jaw Yuan Wang
22 Jan 2020 Reviewed Reviewer Report - Han Zhu
16 Mar 2020 Author responded Author comments - Toshinari Yamashita
2 Apr 2020 Reviewed Reviewer Report - Jaw Yuan Wang
Resubmission - Version 2
16 Mar 2020 Submitted Manuscript version 2
Publishing
24 Apr 2020 Editorially accepted
7 May 2020 Article published 10.1186/s13063-020-04341-y

You can find further information about peer review here.

Back to article page